Crossmark

Reduced risk of cause-specific hospitalisations and all-cause hospitalisation/mortality during treatment with attention-deficit/hyperactivity disorder medications in the course of bipolar disorder: a Swedish registry-based within-subject cohort study

Crossref DOI link: https://doi.org/10.1136/bmjment-2025-302159

Published Online: 2026-03-19

Published Print: 2026-03

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ermis, Cagatay https://orcid.org/0000-0002-8412-8049
Tanskanen, Antti https://orcid.org/0000-0002-3795-3126
Corbeil, Olivier https://orcid.org/0000-0002-4192-853X
Lieslehto, Johannes https://orcid.org/0000-0001-6030-0249
Vieta, Eduard https://orcid.org/0000-0002-0548-0053
Correll, Christoph U https://orcid.org/0000-0002-7254-5646
Mittendorfer-Rutz, Ellenor

Tiihonen, Jari

Taipale, Heidi
Funding

Funding for this research was provided by:

Sigrid Juséliuksen Säätiö (N/A)

Finnish Medical Association (7709)

Vetenskapsrådet (2021-00154)
License Information

License valid from 2026-03-19

Document is current

Any future updates will be listed below